Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
5funds adding
2new positions
$3.85Bheld by those funds
AIThis scan
Compared the Q1 2026 (reportDate 2026-03-31) 13F filings against the Q4 2025 (2025-12-31) filings across the five-fund watchlist: Berkshire Hathaway, Bridgewater Associates, Renaissance Technologies, Citadel Advisors, and Two Sigma. All five returned holdings. After merging by CUSIP, 925 tickers showed net buying; after stripping ETFs, SPACs, foreign issuers, notes, mega-cap retail favorites, and quant-only positions under $100M, ~240 credible signals remained. Five surface where a slow-moving manager (Berkshire or Bridgewater) is present and retail attention is still muted. The single most surprising finding: Berkshire (under Greg Abel's first standalone quarter) tripled New York Times from ~5.07M to ~15.15M shares — a $1.27B stake that puts it inside the top-25 Berkshire equity positions. Delta Air Lines was Berkshire's largest new buy ($2.65B) but was DROPPED from the finalists because the story is already saturated across mainstream media and DAL reported earnings 2026-07-10 — retail attention has spiked, so the edge is gone.
How this scan was run
Per the standard scan: merged holdings by CUSIP across the five funds, computed Q/Q share deltas, required (a) net buyers > net sellers and (b) aggregate share count +25% Q/Q or ≥2 new positions. Put positions were excluded outright as hedges. We required at least one slow-moving fund (Berkshire or Bridgewater) among supporters to promote a candidate to the finalist tier — quant-only signals (RenTech/Citadel/Two Sigma) were preserved in the raw pool but not surfaced unless total supporting AUM ≥ $100M and a Bridgewater or Berkshire co-signed. Junk was stripped by name pattern (ETF/ISHARES/SPDR/ACQUISITION CORP/MTN/WARRANT) and CINS letter-prefix (foreign). Delta Air Lines was excluded despite Berkshire's massive new stake because the position has been saturating financial media since the 2026-05-15 filing (Yahoo, CNBC, 24-7 Wall St) and DAL reported Q2 earnings 2026-07-10 — the "quiet accumulation" premise no longer holds. All "avgEntryPriceEstimate" values are quarter-end 13F value÷shares aggregated across supporting funds — 13F does not disclose cost basis. For Lennar we chose LEN Class A over Class B on liquidity (both are Berkshire-added). All five funds returned holdings; no CUSIP→ticker ambiguity impacted the finalist set (Alphabet Class A was CUSIP-flagged but not surfaced under the mega-cap rule).
#1
NYT
The New York Times Company
Communication ServicesMkt cap $12.3BNext earnings Aug 4, 2026
Price
$74.96
Est. fund entry
$83.73-10.5%
Shares held
20.2M
Position value
$1.69B
Funds that added
Fund
Prior shares
Shares now
Change
Berkshire Hathaway
5.07M
15.1M
+199.0%
Renaissance Technologies
2.29M
2.76M
+20.3%
Two Sigma Investments
1.94M
2.31M
+19.1%
Retail attention 4 of 4 signals quiet
Google Trends15/100quiet
News, 30 days11 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Berkshire's team tripled the NYT stake to $1.27B, promoting it from fringe to core position — the single largest positive delta in Abel's debut filing outside of Alphabet. Digital subscription businesses fit the Buffett playbook precisely: durable pricing power, near-zero incremental capex, and NYT's bundling engine (News + Games + Cooking + Wirecutter + The Athletic) works like a low-visibility toll road. Renaissance and Two Sigma independently added into the same window, adding cross-manager confirmation. The current $75 print is roughly 10% BELOW the funds' Q1 average entry, so retail has not chased the disclosure. Catalyst: 2026-08-04 Q2 print, where Wirecutter affiliate-ad monetization and Games ARPU expansion are not fully in consensus.
What would prove it wrong
Advertising remains cyclical — a US recession would compress the ~30% of revenue still tied to ad spend even as subscription revenue holds. Digital-only subscriber net-adds have decelerated for three consecutive quarters and could disappoint in August.
#2
LEN
Lennar Corporation
Consumer DiscretionaryMkt cap $21.6BNext earnings Sep 17, 2026
Price
$84.27
Est. fund entry
$86.84-3.0%
Shares held
14.0M
Position value
$1.21B
Funds that added
Fund
Prior shares
Shares now
Change
Berkshire Hathaway
7.05M
10.1M
+43.2%
Two Sigma Investments
1.54M
2.60M
+69.5%
Citadel Advisors
1.23M
1.25M
+1.9%
Retail attention 4 of 4 signals quiet
Google Trends22/100quiet
News, 30 days14 articlesquiet
Call/put OI1.50quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Berkshire added ~3.05M Lennar Class A shares (+43%) and retained the B stake — a rare Buffett-scale homebuilder move that echoes the NVR position pattern. Two Sigma more than doubled alongside. The thesis is straightforward: single-family supply is structurally short and Lennar's asset-light spinoff (Millrose Properties, completed early 2025) already transferred the raw-land balance sheet risk, so incremental closings drop closer to gross margin than at any peer. LEN trades at ~9x forward earnings with book value growing through buybacks. Catalyst: 2026-09-17 Q3 print, where FY26 orders and community-count guide is likely to be raised if the Fed cuts in September.
What would prove it wrong
Affordability remains historically stretched; if the 30-year mortgage refuses to break below 6.5%, cancellation rates rise and incentive spend eats margin. Land-cost inflation could compress ROE even with the Millrose structure.
#3
PPL
PPL Corporation
UtilitiesMkt cap $26.5BNext earnings Jul 30, 2026
Price
$35.78
Est. fund entry
$38.20-6.3%
Shares held
12.7M
Position value
$486.9M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
54.9K
425.6K
+675.5%
Citadel Advisors
1.97M
9.11M
+362.8%
Two Sigma Investments
—
3.22M
New position
Retail attention 4 of 4 signals quiet
Google Trends8/100quiet
News, 30 days6 articlesquiet
Call/put OI1.10quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Rare cross-manager conviction on a boring name: Bridgewater grew 7.7x, Citadel 4.6x, Two Sigma opened brand-new — combined $487M added at ~$38 average against a current $35.78 print. The under-the-radar story is PPL's Kentucky and Pennsylvania utility service territories which sit inside the fastest-growing AI-datacenter interconnect queues on the PJM/MISO seams. PPL's five-year capex guide is trending toward $20B, and every dollar of approved rate base earns a regulated ~9.5% ROE. Utilities almost never draw simultaneous macro-hedge and multi-strat interest — this pattern usually foreshadows an income-desk consensus that regulated ROE upside is being under-modeled by the sell-side. Catalyst: 2026-07-30 Q2 print with an expected refresh of the 2026–2030 capex/EPS trajectory.
What would prove it wrong
The Kentucky Public Service Commission's next rate case is the single-largest swing factor — a rejection or capital-recovery lag would reset the multiple. If long-end Treasury yields re-accelerate, utility comps compress irrespective of fundamentals.
#4
EHC
Encompass Health Corporation
Health CareMkt cap $10.9BNext earnings Aug 5, 2026
Price
$110.16
Est. fund entry
$96.73+13.9%
Shares held
3.05M
Position value
$294.9M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
35.4K
46.4K
+31.1%
Renaissance Technologies
68.2K
265.0K
+288.6%
Citadel Advisors
125.1K
515.1K
+311.8%
Two Sigma Investments
804.9K
2.22M
+176.1%
Retail attention 4 of 4 signals quiet
Google Trends6/100quiet
News, 30 days4 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four cross-model managers on the watchlist added — Bridgewater +31%, Two Sigma 2.8x, Citadel 4.1x, Renaissance 3.9x. When macro, quant, and multi-strat all pile into the same rehab-hospital operator inside one quarter, it typically means the CMS reimbursement math has been re-run and something changed. EHC operates the largest inpatient rehabilitation facility (IRF) footprint in the US, is a direct beneficiary of hospitals shortening acute lengths of stay, and is on the receiving end of the MedPAC-recommended FY27 IRF payment update. The stock has quietly re-rated in H1 but 2026 EV/EBITDA is still 11x versus mid-teens historicals. Catalyst: 2026-08-05 Q2 print, with the final CMS FY27 IRF PPS rule expected in early August.
What would prove it wrong
Nursing labor cost inflation remains the largest earnings variable — one-quarter of wage pressure has repeatedly compressed the multiple. Any adverse CMS decision in the November final rule (rehabilitation compliance thresholds) would knock the stock 10%+.
#5
RMD
ResMed Inc.
Health CareMkt cap $29.7BNext earnings Aug 6, 2026
Price
$203.87
Est. fund entry
$224.48-9.2%
Shares held
739.5K
Position value
$166.0M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
32.9K
39.2K
+19.2%
Citadel Advisors
86.7K
387.8K
+347.3%
Two Sigma Investments
—
312.5K
New position
Retail attention 4 of 4 signals quiet
Google Trends18/100quiet
News, 30 days12 articlesquiet
Call/put OI1.30quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Contrarian re-entry: the GLP-1/Ozempic panic that gutted RMD in 2023–2024 is reversing quietly on the accumulation tape. Citadel took its stake up 4.5x and Two Sigma opened fresh, alongside Bridgewater. The emerging clinical read-through — reinforced by multiple 2025 sleep-medicine studies — is that GLP-1 patients get diagnosed with sleep apnea at higher rates and stay on CPAP longer, which is the OPPOSITE of the original bear case. RMD prints ~22% operating margins on a 90%+ recurring mask/consumables mix; hardware plus consumables compounds when patient pool grows. Current $203.87 is ~9% below the funds' Q1 entry and RMD has not been on any retail hotlist since 2023. Catalyst: 2026-08-06 FY-Q4 print plus expected AI-connected AirSense 12 launch details.
What would prove it wrong
The clinical thesis reverses immediately if any Zepbound or tirzepatide Phase 3 read-out at AHA or ATS shows sleep-apnea remission on GLP-1 monotherapy strong enough to displace CPAP. Payer pricing pressure on masks and consumables is an ongoing headwind that would erode the recurring-revenue story.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.